Advertisement

Tea Polyphenols in Parkinson’s Disease

  • Mario CaruanaEmail author
  • Neville Vassallo
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 863)

Abstract

Parkinson’s disease (PD) is a common motor neurodegenerative disorder with multifactorial etiology that is an increasing burden on our aging society. PD is characterized by nigrostriatal degeneration which might involve oxidative stress, α-synuclein (αS) aggregation, dysregulation of redox metal homeostasis and neurotoxicity. Although the exact cause remains unknown, both genetic and environmental factors have been implicated. Among the various environmental factors tea consumption has attracted increasing interest, as besides being one of the most consumed beverages in the world, tea contains specific polyphenols which can play an important role in delaying the onset or halting the progression of PD. Green and black teas are rich sources of polyphenols, the most abundant being epigallocatechin-3-gallate (EGCG) and theaflavins. There is now consistent mechanistic data on the neuroprotective and neuroregenerative effects of tea polyphenols, indicating that they do not just possess anti-oxidant or anti-chelating properties but may directly interfere with aggregation of the αS protein and modulate intracellular signalling pathways, both in vitro and in animal models. EGCG in green tea has been by far the most studied compound and therefore future investigations should address more the effects of other polyphenols, especially theaflavins in black tea. Nevertheless, despite significant data on their potential neuroprotective effects, clinical studies are still very limited and to date only EGCG has reached phase II trials. This review collates the current knowledge of tea polyphenols and puts into perspective their potential to be considered as nutraceuticals that target various pathologies in PD.

Keywords

Parkinson’s disease Alpha-synuclein Tea Epigallocatechin-gallate Theaflavins Neuroprotection 

References

  1. Abd El Mohsen MM, Kuhnle G, Rechner AR, Schroeter H, Rose S, Jenner P, Rice-Evans CA (2002) Uptake and metabolism of epicatechin and its access to the brain after oral ingestion. Free Radic Biol Med 33(12):1693–1702PubMedGoogle Scholar
  2. Adachi N, Tomonaga S, Tachibana T, Denbow DM, Furuse M (2006) (−)-Epigallocatechin gallate attenuates acute stress responses through GABAergic system in the brain. Eur J Pharmacol 531(1–3):171–175PubMedGoogle Scholar
  3. Aherne SA, O’Brien NM (2002) Dietary flavonols: chemistry, food content, and metabolism. Nutrition 18(1):75–81PubMedGoogle Scholar
  4. Albani D, Polito L, Signorini A, Forloni G (2010) Neuroprotective properties of resveratrol in different neurodegenerative disorders. Biofactors 36(5):370–376PubMedGoogle Scholar
  5. Amit T, Avramovich-Tirosh Y, Youdim MBH, Mandel S (2008) Targeting multiple Alzheimer’s disease etiologies with multimodal neuroprotective and neurorestorative iron chelators. FASEB J 22(5):1296–1305PubMedGoogle Scholar
  6. Anandhan A, Janakiraman U, Manivasagam T (2012a) Theaflavin ameliorates behavioral deficits, biochemical indices and monoamine transporters expression against subacute 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced mouse model of Parkinson’s disease. Neuroscience 218:257–267PubMedGoogle Scholar
  7. Anandhan A, Tamilselvam K, Radhiga T, Rao S, Essa MM, Manivasagam T (2012b) Theaflavin, a black tea polyphenol, protects nigral dopaminergic nerons against chronic MPTP/probenecid induced Parkinson’s disease. Brain Res 1433:104–113PubMedGoogle Scholar
  8. Aron PM, Kennedy JA (2008) Flavan-3-ols: nature, occurrence and biological activity. Mol Nutr Food Res 52(1):79–104PubMedGoogle Scholar
  9. Ascherio A, Zhang SM, Hernan MA, Kawachi I, Colditz GA, Speizer FE, Willett WC (2001) Prospective study of caffeine consumption and risk of Parkinson’s disease in men and women. Ann Neurol 50:56–63PubMedGoogle Scholar
  10. Astill C, Birch MR, Dacombe C, Humphrey PG, Martin PT (2001) Factors affecting the caffeine and polyphenol contents of black and green tea infusions. J Agric Food Chem 49(11):5340–5347PubMedGoogle Scholar
  11. Auger C, Mullen W, Hara Y, Crozier A (2008) Bioavailability of polyphenon E flavan-3-ols in humans with an ileostomy. J Nutr 138(8):1542Google Scholar
  12. Bae SY, Kim S, Hwang H, Kim HK, Yoon HC, Kim JH, Lee S, Kim TD (2010) Amyloid formation and disaggregation of α-synuclein and its tandem repeat (α-TR). Biochem Biophys Res Commun 400:531–536PubMedGoogle Scholar
  13. Balentine DA, Wiseman SA, Bouwens LC (1997) The chemistry of tea flavonoids. Crit Rev Food Sci Nutr 37:693–704PubMedGoogle Scholar
  14. Barnham KJ, Bush AI (2008) Metals in Alzheimer’s and Parkinson’s diseases. Curr Opin Chem Biol 12(2):222–228PubMedGoogle Scholar
  15. Bastianetto S (2002) Red wine consumption and brain aging. Nutrition 18(5):432–433PubMedGoogle Scholar
  16. Bastianetto S, Quirion R (2004) Natural antioxidants and neurodegenerative diseases. Front Biosci 9:3447–3452PubMedGoogle Scholar
  17. Bastianetto S, Yao Z-X, Papadopoulos V, Quirion R (2006) Neuroprotective effects of green and black teas and their catechin gallate esters against beta-amyloid-induced toxicity. Eur J Neurosci 23(1):55–64PubMedGoogle Scholar
  18. Beecher GR (2003) Overview of dietary flavonoids: nomenclature, occurrence and intake. J Nutr 133(10):3254Google Scholar
  19. Berhanu WM, Masunov AE (2010) Natural polyphenols as inhibitors of amyloid aggregation. Molecular dynamics study of GNNQQNY heptapeptide decamer. Biophys Chem 149(1–2):12–21PubMedGoogle Scholar
  20. Bieschke J, Russ J, Friedrich RP, Ehrnhoefer DE, Wobst H, Neugebauer K, Wanker EE (2010) EGCG remodels mature alpha-synuclein and amyloid-beta fibrils and reduces cellular toxicity. Proc Natl Acad Sci U S A 107:7710–7715PubMedCentralPubMedGoogle Scholar
  21. Blazovics A, Lugasi A, Kemeny T, Hagymasi K, Kery A (2000) Membrane stabilising effects of natural polyphenols and flavonoids from Sempervivum tectorum on hepatic microsomal mixed-function oxidase system in hyperlipidemic rats. J Ethnopharmacol 73(3):479–485PubMedGoogle Scholar
  22. Braak H, Ghebremedhin E, Rub U, Bratzke H, Del Tredici K (2004) Stages in the development of Parkinson’s disease-related pathology. Cell Tissue Res 318(1):121–134PubMedGoogle Scholar
  23. Büeler H (2009) Impaired mitochondrial dynamics and function in the pathogenesis of Parkinson’s disease. Exp Neurol 218:235–246PubMedGoogle Scholar
  24. Calixto JB, Campos MM, Otuki MF, Santos AR (2004) Anti-inflammatory compounds of plant origin. Part II. Modulation of pro-inflammatory cytokines, chemokines and adhesion molecules. Planta Med 70(2):93–103PubMedGoogle Scholar
  25. Camilleri A, Vassallo N (2014) The centrality of mitochondria in the pathogenesis and treatment of Parkinson’s disease. CNS Neurosci Ther 20(7):591–602PubMedGoogle Scholar
  26. Camilleri A, Zarb C, Caruana M, Ostermeier U, Ghio S, Hogen T, Schmidt F, Giese A, Vassallo N (2013) Mitochondrial membrane permeabilisation by amyloid aggregates and protection by polyphenols. Biochim Biophys Acta 1828(11):2532–2543PubMedGoogle Scholar
  27. Campos-Esparza R, Torres-Ramos MA (2010) Neuroprotection by natural polyphenols: molecular mechanisms. Cent Nerv Syst Agents Med Chem 10:269–277Google Scholar
  28. Cao G, Giovanoni M, Prior RL (1996) Antioxidant capacity in different tissues of young and old rats. Proc Soc Exp Biol Med 211(4):359–365PubMedGoogle Scholar
  29. Caruana M, Vassallo N (2011) The potential role of dietary polyphenols in Parkinson’s disease. Malta Med J 23(3):52–55Google Scholar
  30. Caruana M, Vassallo N (2014) Select polyphenols that protect mitochondria against amyloid aggregates in Alzheimer’s and Parkinson’s disease. Xjenza Online 2:17–25Google Scholar
  31. Caruana M, Hogen T, Levin J, Hillmer A, Giese A, Vassallo N (2011) Inhibition and disaggregation of α-synuclein oligomers by natural polyphenolic compounds. FEBS Lett 585(8):1113–1120PubMedGoogle Scholar
  32. Caruana M, Neuner J, Högen T, Schmidt F, Scerri C, Giese A, Vassallo N (2012) Polyphenolic compounds are novel protective agents against lipid membrane damage by α-synuclein aggregates in vitro. Biochim Biophys Acta 1818(11):2502–2510PubMedGoogle Scholar
  33. Chan DK, Woo J, Ho SC, Pang CP, Law LK, Ng PW, Hung WT, Kwok T, Hui E, Orr K, Leung MF, Kay R (1998) Genetic and environmental risk factors for Parkinson’s disease in a Chinese population. J Neurol Neurosurg Psychiatry 65(5):781–784PubMedCentralPubMedGoogle Scholar
  34. Chan P, Qin Z, Zheng Z, Zhang L, Fang X, Sun F, Gu Z, Chen S, Ma J, Meng C, Langston JW, Tanner CM (2009) A randomized, double-blind, placebo controlled, delayed start study to assess safety, tolerability and efficacy of green tea polyphenols in Parkinson’s disease. XVIII WFN World Congress on Parkinson’s Disease and Related Disorders, Miami Beach, 13–16 Dec 2009Google Scholar
  35. Chaturvedi RK, Shukla S, Seth K, Chauhan S, Sinha C, Shukla Y, Agrawal AK (2006) Neuroprotective and neurorescue effect of black tea extract in 6-hydroxydopamine-lesioned rat model of Parkinson’s disease. Neurobiol Dis 22(2):421–434PubMedGoogle Scholar
  36. Checkoway H, Powers K, Smith-Weller T, Franklin GM, Longstreth WT, Swanson PD (2002) Parkinson’s disease risks associated with cigarette smoking, alcohol consumption, and caffeine intake. Am J Epidemiol 155(8):732–738PubMedGoogle Scholar
  37. Chen CM, Lin JK, Liu SH, Lin-Shiau SY (2008) Novel regimen through combination of memantine and tea polyphenol for neuroprotection against brain excitotoxicity. J Neurosci Res 86(12):2696–2704PubMedGoogle Scholar
  38. Chen R, Wang JB, Zhang XQ, Ren J, Zeng CM (2011) Green tea polyphenol epigallocatechin-3-gallate (EGCG) induced intermolecular cross-linking of membrane proteins. Arch Biochem Biophys 507(2):343–349PubMedGoogle Scholar
  39. Chen M, Wang T, Yue F, Li X, Wang P, Li Y, Chan P, Yu S (2014) Tea polyphenols alleviate motor impairments, dopaminergic neuronal injury, and cerebral α-synuclein aggregation in MPTP-intoxicated parkinsonian monkeys. Neuroscience 286:383–392PubMedGoogle Scholar
  40. Choi JY, Park CS, Kim DJ, Cho MH, Jin BK, Pie JE, Chung WG (2002) Prevention of nitric oxide-mediated 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinson’s disease in mice by tea phenolic epigallocatechin 3-gallate. Neurotoxicology 23(3):367–374PubMedGoogle Scholar
  41. Choi YJ, Jeong YJ, Lee YJ, Kwon HM, Kang YH (2005) (−)Epigallocatechin gallate and quercetin enhance survival signaling in response to oxidant-induced human endothelial apoptosis. J Nutr 135(4):707–713PubMedGoogle Scholar
  42. Choi DY, Lee YJ, Hong JT, Lee HJ (2012) Antioxidant properties of natural polyphenols and their therapeutic potentials for Alzheimer’s disease. Brain Res Bull 87(2–3):144–153PubMedGoogle Scholar
  43. Chow HH, Cai Y, Hakim IA, Crowell JA, Shahi F, Brooks CA, Dorr RT, Hara Y, Alberts DS (2003) Pharmacokinetics and safety of green tea polyphenols after multiple-dose administration of epigallocatechin gallate and polyphenon E in healthy individuals. Clin Cancer Res 9(9):3312–3319PubMedGoogle Scholar
  44. Chow HH, Hakim IA, Vining DR, Crowell JA, Ranger-Moore J, Chew WM, Celaya CA, Rodney SR, Hara Y, Alberts DS (2005) Effects of dosing condition on the oral bioavailability of green tea catechins after single-dose administration of Polyphenon E in healthy individuals. Clin Cancer Res 11(12):4627–4633PubMedGoogle Scholar
  45. Chun OK, Chung SJ, Song WO (2007) Estimated dietary flavonoid intake and major food sources of U.S. adults. J Nutr 137(5):1244–1252PubMedGoogle Scholar
  46. Conway KA, Rochet JC, Bieganski RM, Lansbury PT (2001) Kinetic stabilization of the alpha-synuclein protofibril by a dopamine-alpha-synuclein adduct. Science 294(5545):1346–1349PubMedGoogle Scholar
  47. Costa J, Lunet N, Santos C, Santos J, Vaz-Carneiro A (2010) Caffeine exposure and the risk of Parkinson’s disease: a systematic review and meta-analysis of observational studies. J Alzheimers Dis 20:221–238Google Scholar
  48. Crozier A, Jaganath IB, Clifford MN (2009) Dietary phenolics: chemistry, bioavailability and effects on health. Nat Prod Rep 26(8):1001–1043PubMedGoogle Scholar
  49. D’Archivio M, Filesi C, Di Benedetto R, Gargiulo R, Giovannini C, Masella R (2007) Polyphenols, dietary sources and bioavailability. Ann Ist Super Sanita 43:348–361PubMedGoogle Scholar
  50. Dajas F, Rivera F, Blasina F, Arredondo F, Echeverry C, Lafon L, Morquio A, Heinzen H, Heizen H (2003) Cell culture protection and in vivo neuroprotective capacity of flavonoids. Neurotox Res 5(6):425–432PubMedGoogle Scholar
  51. de Lau LM, Breteler MM (2006) Epidemiology of Parkinson’s disease. Lancet Neurol 5:525–535PubMedGoogle Scholar
  52. Dorsey ER, Constantinescu R, Thompson JP, Biglan KM, Holloway RG, Kieburtz K, Marshall FJ, Ravina BM, Schifitto G, Siderowf A, Tanner CM (2007) Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology 68:384–386PubMedGoogle Scholar
  53. Duchnowicz P, Bors M, Podsędek A, Koter-Michalak M, Broncel M (2012) Effect of polyphenols extracts from Brassica vegetables on erythrocyte membranes (in vitro study). Environ Toxicol Pharmacol 34(3):783–790PubMedGoogle Scholar
  54. Ehrnhoefer DE, Bieschke J, Boeddrich A, Herbst M, Masino L, Lurz R, Engemann S, Pastore A, Wanker EE (2008) EGCG redirects amyloidogenic polypeptides into unstructured, off-pathway oligomers. Nat Struct Mol Biol 15:558–566PubMedGoogle Scholar
  55. Engel MFM, van den Akker CC, Schleeger M, Velikov KP, Koenderink GH, Bonn M (2012) The polyphenol EGCG inhibits amyloid formation less efficiently at phospholipid interfaces than in bulk solution. J Am Chem Soc 134(36):14781–14788PubMedGoogle Scholar
  56. Erdman JW, Balentine D, Arab L, Beecher G, Dwyer JT, Folts J, Harnly J, Hollman P, Keen CL, Mazza G, Messina M, Scalbert A, Vita J, Williamson G, Burrowes J (2007) Flavonoids and heart health: proceedings of the ILSI North America Flavonoids Workshop, May 31-June 1, 2005, Washington, DC. J Nutr 137(3 Suppl 1):737Google Scholar
  57. Fall PA, Fredrikson M, Axelson O, Granérus AK (1999) Nutritional and occupational factors influencing the risk of Parkinson’s disease: a case–control study in south eastern Sweden. Mov Disord 14:28–37PubMedGoogle Scholar
  58. Faria A, Pestana D, Teixeira D, Couraud PO, Romero I, Weksler B, de Freitas V, Mateus N, Calhau C (2011) Insights into the putative catechin and epicatechin transport across blood–brain barrier. Food Funct 2(1):39–44PubMedGoogle Scholar
  59. Frei B, Higdon JV (2003) Antioxidant activity of tea polyphenols in vivo: evidence from animal studies. J Nutr 133:3275–3284Google Scholar
  60. Friedman A, Galazka-Friedman J (2001) The current state of free radicals in Parkinson’s disease: nigral iron as a trigger of oxidative stress. Adv Neurol 86:137–142PubMedGoogle Scholar
  61. Fukae J, Mizuno Y, Hattori N (2007) Mitochondrial dysfunction in Parkinson’s disease. Mitochondrion 7(1–2):58–62PubMedGoogle Scholar
  62. Gao X, Cassidy A, Schwarzschild MA, Rimm EB, Ascherio A (2012) Habitual intake of dietary flavonoids and risk of Parkinson disease. Neurology 78(15):1138–1145PubMedCentralPubMedGoogle Scholar
  63. Gazit E (2002) A possible role for π-stacking in the self-assembly of amyloid fibrils. FASEB J 16:77–83PubMedGoogle Scholar
  64. Gerlach M, Maetzler W, Broich K, Hampel H, Rems L, Reum T, Riederer P, Stoffler A, Streffer J, Berg D (2012) Biomarker candidates of neurodegeneration in Parkinson’s disease for the evaluation of disease-modifying therapeutics. J Neural Transm 119(1):39–52PubMedCentralPubMedGoogle Scholar
  65. Ghosh D, Scheepens A (2009) Vascular action of polyphenols. Mol Nutr Food Res 53(3):322–331PubMedGoogle Scholar
  66. Graham HN (1992) Green tea composition, consumption, and polyphenol chemistry. Prev Med 21(3):334–350PubMedGoogle Scholar
  67. Grelle G, Otto A, Lorenz M, Frank RF, Wanker EE, Bieschke J (2011) Black tea theaflavins inhibit formation of toxic amyloid-β and α-synuclein fibrils. Biochemistry 50(49):10624–10636PubMedGoogle Scholar
  68. Guo S, Yan J, Yang T, Yang X, Bezard E, Zhao B (2007) Protective effects of green tea polyphenols in the 6-OHDA rat model of Parkinson’s disease through inhibition of ROS-NO pathway. Biol Psychiatry 62(12):1353–1362PubMedGoogle Scholar
  69. Haenen GR, Paquay JB, Korthouwer RE, Bast A (1997) Peroxynitrite scavenging by flavonoids. Biochem Biophys Res Commun 236(3):591–593PubMedGoogle Scholar
  70. Hancock DB, Martin ER, Stajich JM, Jewett R, Stacy MA, Scott BL, Vance JM, Scott WK (2007) Smoking, caffeine, and nonsteroidal anti-inflammatory drugs in families with Parkinson disease. Arch Neurol 64:576–580PubMedGoogle Scholar
  71. Harbowy ME, Ballentine DA (1997) Tea chemistry. Crit Rev Plant Sci 16:415–480Google Scholar
  72. Hartmann A, Hirsch EC (2001) Parkinson’s disease. The apoptosis hypothesis revisited. Adv Neurol 86:143–153PubMedGoogle Scholar
  73. Hendrich AB (2006) Flavonoid-membrane interactions: possible consequences for biological effects of some polyphenolic compounds. Acta Pharmacol Sin 27:27–40PubMedGoogle Scholar
  74. Henning SM, Choo JJ, Heber D (2008) Nongallated compared with gallated flavan-3-ols in green and black tea are more bioavailable. J Nutr 138(8):1534Google Scholar
  75. Hernan MA, Takkouche B, Caamano-Isorna F, Gestal-Otero JJ (2002) A meta-analysis of coffee drinking, cigarette smoking, and the risk of Parkinson’s disease. Ann Neurol 52(3):276–284PubMedGoogle Scholar
  76. Hertog MG, Feskens EJ, Hollman PC, Katan MB, Kromhout D (1993) Dietary antioxidant flavonoids and risk of coronary heart disease: the Zutphen Elderly Study. Lancet 342(8878):1007–1011PubMedGoogle Scholar
  77. Higdon JV, Frei B (2003) Tea catechins and polyphenols: health effects, metabolism, and antioxidant functions. Crit Rev Food Sci Nutr 43(1):89–143PubMedGoogle Scholar
  78. Hollman PC, Van het Hof KH, Tijburg LB, Katan MB (2001) Addition of milk does not affect the absorption of flavonols from tea in man. Free Radic Res 34:297–300PubMedGoogle Scholar
  79. Hu G, Bidel S, Jousilahti P, Antikainen R, Tuomilehto J (2007) Coffee and tea consumption and the risk of Parkinson’s disease. Mov Disord 22(15):2242–2248PubMedGoogle Scholar
  80. Huang CC, Wu WB, Fang JY, Chiang HS, Chen SK, Chen BH, Chen YT, Hung CF (2007) (−)-Epicatechin-3-gallate, a green tea polyphenol is a potent agent against UVB-induced damage in HaCaT keratinocytes. Molecules 12(8):1845–1858PubMedGoogle Scholar
  81. Hudson SA, Ecroyd H, Dehle FC, Musgrave IF, Carver JA (2009) (−)-epigallocatechin-3-gallate (EGCG) maintains kappa-casein in its pre-fibrillar state without redirecting its aggregation pathway. J Mol Biol 392(3):689–700PubMedGoogle Scholar
  82. Hwang SL, Yen GC (2009) Modulation of Akt, JNK, and p38 activation is involved in citrus flavonoid-mediated cytoprotection of PC12 cells challenged by hydrogen peroxide. J Agric Food Chem 57:2576–2582PubMedGoogle Scholar
  83. Jankovic J (2008) Parkinson’s disease: clinical features and diagnosis. J Neurol Neurosurg Psychiatry 79(4):368–376PubMedGoogle Scholar
  84. Jeong JH, Kim HJ, Lee TJ, Kim MK, Park ES, Choi BS (2004) Epigallocatechin 3-gallate attenuates neuronal damage induced by 3-hydroxykynurenine. Toxicology 195(1):53–60PubMedGoogle Scholar
  85. Jimenez-Del-Rio M, Guzman-Martinez C, Velez-Pardo C (2010) The effects of polyphenols on survival and locomotor activity in Drosophila melanogaster exposed to iron and paraquat. Neurochem Res 35:227–238PubMedGoogle Scholar
  86. Johnston TH, Brotchie JM (2004) Drugs in development for Parkinson’s disease. Curr Opin Investig Drugs 5:720–726PubMedGoogle Scholar
  87. Kandinov B, Giladi N, Korczyn AD (2009) Smoking and tea consumption delay onset of Parkinson’s disease. Parkinsonism Relat Disord 15(1):41–46PubMedGoogle Scholar
  88. Kaur D, Yantiri F, Rajagopalan S, Kumar J, Mo JQ, Boonplueang R, Viswanath V, Jacobs R, Yang L, Beal MF, DiMonte D, Volitaskis I, Ellerby L, Cherny RA, Bush AI, Andersen JK (2003) Genetic or pharmacological iron chelation prevents MPTP-induced neurotoxicity in vivo: a novel therapy for Parkinson’s disease. Neuron 37(6):899–909PubMedGoogle Scholar
  89. Kazantsev AG, Kolchinsky AM (2008) Central role of alpha-synuclein oligomers in neurodegeneration in Parkinson disease. Arch Neurol 65(12):1577–1581PubMedGoogle Scholar
  90. Khokhar S, Magnusdottir SGM (2002) Total phenol, catechin, and caffeine contents of teas commonly consumed in the United Kingdom. J Agric Food Chem 50(3):565–570PubMedGoogle Scholar
  91. Kishido T, Unno K, Yoshida H, Choba D, Fukutomi R, Asahina S, Iguchi K, Oku N, Hoshino M (2007) Decline in glutathione peroxidase activity is a reason for brain senescence: consumption of green tea catechin prevents the decline in its activity and protein oxidative damage in ageing mouse brain. Biogerontology 8(4):423–430PubMedGoogle Scholar
  92. Kumamoto M, Sonda T, Nagayama K, Tabata M (2001) Effects of pH and metal ions on antioxidative activities of catechins. Biosci Biotechnol Biochem 65(1): 126–132PubMedGoogle Scholar
  93. Kumar S, Pandey AK (2013) Chemistry and biological activities of flavonoids: an overview. Scientific World Journal 2013:162750PubMedCentralPubMedGoogle Scholar
  94. Kyle JA, Morrice PC, McNeill G, Duthie GG (2007) Effects of infusion time and addition of milk on content and absorption of polyphenols from black tea. J Agric Food Chem 55(12):4889–4894PubMedGoogle Scholar
  95. Kyoung AK, Zhi HW, Rui Z, Mei JP, Ki CK, Sam SK, Young WK, Jongsung L, Deokhoon P, Jin WH (2010) Myricetin protects cells against oxidative stress-induced apoptosis via regulation of PI3K/Akt and MAPK signalling pathways. Int J Mol Sci 11:4348–4360Google Scholar
  96. Lashuel HA, Petre BM, Wall J, Simon M, Nowak RJ, Walz T, Lansbury PT Jr (2002) Alpha-synuclein, especially the Parkinson’s disease-associated mutants, forms pore-like annular and tubular protofibrils. J Mol Biol 322:1089–1102PubMedGoogle Scholar
  97. Leaver KR, Allbutt HN, Creber NJ, Kassiou M, Henderson JM (2009) Oral pre-treatment with epigallocatechin gallate in 6-OHDA lesioned rats produces subtle symptomatic relief but not neuroprotection. Brain Res Bull 80(6):397–402PubMedGoogle Scholar
  98. Lee MJ, Maliakal P, Chen L, Meng X, Bondoc FY, Prabhu S, Lambert G, Mohr S, Yang CS (2002) Pharmacokinetics of tea catechins after ingestion of green tea and (−)-epigallocatechin-3-gallate by humans: formation of different metabolites and individual variability. Cancer Epidemiol Biomark Prev 11:1025–1032Google Scholar
  99. Leung LK, Su Y, Chen R, Zhang Z, Huang Y, Chen ZY (2001) Theaflavins in black tea and catechins in green tea are equally effective antioxidants. J Nutr 131(9):2248–2251PubMedGoogle Scholar
  100. Levites Y, Weinreb O, Maor G, Youdim MB, Mandel S (2001) Green tea polyphenol (−)-epigallocatechin-3-gallate prevents N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced dopaminergic neurodegeneration. J Neurochem 78:1073–1082PubMedGoogle Scholar
  101. Levites Y, Youdim MB, Maor G, Mandel S (2002a) Attenuation of 6-hydroxydopamine (6-OHDA)-induced nuclear factor-kappaB (NF-kappaB) activation and celldeath by tea extracts in neuronal cultures. Biochem Pharmacol 63(1):21–29PubMedGoogle Scholar
  102. Levites Y, Amit T, Youdim MB, Mandel S (2002b) Involvement of protein kinase C activation and cell survival/ cell cycle genes in green tea polyphenol (−)-epigallocatechin 3-gallate neuroprotective action. J Biol Chem 277:30574–30580PubMedGoogle Scholar
  103. Li S, Schoenberg BS, Wang CC, Cheng X-M, Rui D-Y, Bolis CL, Schoenberg BG (1985) A prevalence survey of Parkinson’s disease and other movement disorders in the People’s Republic of China. Arch Neurol 42:655–657PubMedGoogle Scholar
  104. Li FJ, Ji HF, Shen L (2012) A meta-analysis of tea drinking and risk of Parkinson’s disease. Scientific World Journal 2012:923464PubMedCentralPubMedGoogle Scholar
  105. Logroscino G (2005) The role of early life environmental risk factors in Parkinson disease: what is the evidence? Environ Health Perspect 113:1234–1238PubMedCentralPubMedGoogle Scholar
  106. López-Lázaro M (2009) Distribution and biological activities of the flavonoid luteolin. Mini Rev Med Chem 9:31–59PubMedGoogle Scholar
  107. Lotito SB, Frei B (2006) Consumption of flavonoid-rich foods and increased plasma antioxidant capacity in humans: cause, consequence, or epiphenomenon? Free Radic Biol Med 41(12):1727–1746PubMedGoogle Scholar
  108. Luczaj W, Skrzydlewska E (2005) Antioxidative properties of black tea. Prev Med 40:910–918PubMedGoogle Scholar
  109. Mandel S, Youdim MB (2004) Catechin polyphenols: neurodegeneration and neuroprotection in neurodegenerative diseases. Free Radic Biol Med 37:304–317PubMedGoogle Scholar
  110. Mandel S, Weinreb O, Amit T, Youdim MB (2004) Cell signaling pathways in the neuroprotective actions of the green tea polyphenol (−)-epigallocatechin-3-gallate: Implications for neurodegenerative diseases. J Neurochem 88:1555–1569PubMedGoogle Scholar
  111. Mandel SA, Amit T, Weinreb O, Reznichenko L, Youdim MBH (2008) Simultaneous manipulation of multiple brain targets by green tea catechins: a potential neuroprotective strategy for Alzheimer and Parkinson diseases. CNS Neurosci Ther 14(4):352–365PubMedGoogle Scholar
  112. Masuda M, Suzuki N, Taniguchi S, Oikawa T, Nonaka T, Iwatsubo T, Hisanaga S-i, Goedert M, Hasegawa M (2006) Small molecule inhibitors of alpha-synuclein filament assembly. Biochemistry 45(19):6085–6094PubMedGoogle Scholar
  113. McGeer PL, Yasojima K, McGeer EG (2001) Inflammation in Parkinson’s disease. Adv Neurol 86:83–89PubMedGoogle Scholar
  114. McKay DL, Blumberg JB (2002) The role of tea in human health: an update. JACN 21:1–13Google Scholar
  115. Meng X, Munishkina LA, Fink AL, Uversky VN (2009) Molecular mechanisms underlying the flavonoid-induced inhibition of alpha-synuclein fibrillation. Biochemistry 48(34):8206–8224PubMedGoogle Scholar
  116. Meng X, Munishkina LA, Fink AL, Uversky VN (2010) Effects of various flavonoids on the α-synuclein fibrillation process. Parkinsons Dis 2010:650794PubMedCentralPubMedGoogle Scholar
  117. Mercer LD, Kelly BL, Horne MK, Beart PM (2005) Dietary polyphenols protect dopamine neurons from oxidative insults and apoptosis: investigations in primary rat mesencephalic cultures. Biochem Pharmacol 69(2):339–345PubMedGoogle Scholar
  118. Moon JK, Shibamoto T (2009) Antioxidant assays for plant and food components. J Agric Food Chem 57(5):1655–1666PubMedGoogle Scholar
  119. Na HK, Kim EH, Jung JH, Lee HH, Hyun JW, Surh YJ (2008) (−)-Epigallocatechin gallate induces Nrf2-mediated antioxidant enzyme expression via activation of PI3K and ERK in human mammary epithelial cells. Arch Biochem Biophys 476(2):171–177PubMedGoogle Scholar
  120. Nakagawa K, Miyazawa T (1997) Absorption and distribution of tea catechin, (−)-epigallocatechin-3-gallate, in the rat. J Nutr Sci Vitaminol (Tokyo) 43(6):679–684Google Scholar
  121. Nakagawa T, Yokozawa T (2002) Direct scavenging of nitric oxide and superoxide by green tea. Food Chem Toxicol 40(12):1745–1750PubMedGoogle Scholar
  122. Nanjo F, Goto K, Seto R, Suzuki M, Sakai M, Hara Y (1996) Scavenging effects of tea catechins and their derivatives on 1,1-diphenyl-2-picrylhydrazyl radical. Free Radic Biol Med 21:895–902PubMedGoogle Scholar
  123. Obrenovich ME, Nair NG, Beyaz A, Aliev G, Reddy VP (2010) The role of polyphenolic antioxidants in health, disease, and aging. Rejuvenation Res 13(6):631–643PubMedGoogle Scholar
  124. Oku N, Matsukawa M, Yamakawa S, Asai T, Yahara S, Hashimoto F, Akizawa T (2003) Inhibitory effect of green tea polyphenols on membrane-type 1 matrix metalloproteinase, MT1-MMP. Biol Pharm Bull 26(9):1235–1238PubMedGoogle Scholar
  125. Olanow CW, Rascol O, Hauser R, Feigin PD, Jankovic J, Lang A, Langston W, Melamed E, Poewe W, Stocchi F, Tolosa E, ADAGIO Study Investigators (2009) A double-blind, delayed-start trial of rasagiline in Parkinson’s disease. N Engl J Med 361(13):1268–1278PubMedGoogle Scholar
  126. Ono K, Yamada M (2006) Antioxidant compounds have potent anti-fibrillogenic and fibril-destabilizing effects for alpha-synuclein fibrils in vitro. J Neurochem 97:105–115PubMedGoogle Scholar
  127. Paganini-Hill A (2001) Risk factors for Parkinson’s disease: the Leisure World cohort study. Neuroepidemiology 20:118–124PubMedGoogle Scholar
  128. Pan T, Jankovic J, Le W (2003) Potential therapeutic properties of green tea polyphenols in Parkinson’s disease. Drugs Aging 20(10):711–721PubMedGoogle Scholar
  129. Pan T, Fei J, Zhou X, Jankovic J, Le W (2004) Effects of green tea polyphenols on dopamine uptake and on MPPS-induced dopamine neuron injury. Life Sci 72:1073–1083Google Scholar
  130. Periquet M, Fulga T, Myllykangas L, Schlossmacher MG, Feany MB (2007) Aggregated alpha-synuclein mediates dopaminergic neurotoxicity in vivo. J Neurosci 27(12):3338–3346PubMedGoogle Scholar
  131. Perron NR, Brumaghim JL (2009) A review of the antioxidant mechanisms of polyphenol compounds related to iron binding. Cell Biochem Biophys 53(2):75–7100PubMedGoogle Scholar
  132. Perron NR, Hodges JN, Jenkins M, Brumaghim JL (2008) Predicting how polyphenol antioxidants prevent DNA damage by binding to iron. Inorg Chem 47(14):6153–6161PubMedGoogle Scholar
  133. Perron NR, Wang HC, Deguire SN, Jenkins M, Lawson M, Brumaghim JL (2010) Kinetics of iron oxidation upon polyphenol binding. Dalton Trans 39(41):9982–9987PubMedGoogle Scholar
  134. Porat Y, Mazor Y, Efrat S, Gazit E (2004) Inhibition of islet amyloid polypeptide fibril formation: a potential role for heteroaromatic interactions. Biochemistry 43(45):14454–14462PubMedGoogle Scholar
  135. Porat Y, Abramowitz A, Gazit E (2006) Inhibition of amyloid fibril formation by polyphenols: structural similarity and aromatic interactions as a common inhibition mechanism. Chem Biol Drug Des 67(1):27–37PubMedGoogle Scholar
  136. Preux PM, Condet A, Anglade C, Druet-Cabanac M, Debrock C, Macharia W, Couratier P, Boutros-Toni F, Dumas M (2000) Parkinson’s disease and environmental factors. Matched caseecontrol study in the Limousin region, France. Neuroepidemiology 19(6):333–337PubMedGoogle Scholar
  137. Quintana BJ, Allam MF, Del Castillo AS, Navajas RF (2009) Parkinson’s disease and tea: a quantitative review. J Am Coll Nutr 28(1):1–6Google Scholar
  138. Quist A, Doudevski I, Lin H, Azimova R, Ng D, Frangione B, Kagan B, Ghiso J, Lal R (2005) Amyloid ion channels: a common structural link for protein-misfolding disease. Proc Natl Acad Sci U S A 102(30):10427–10432PubMedCentralPubMedGoogle Scholar
  139. Rahman M, Riaz M, Desai UR (2007) Synthesis of biologically relevant biflavanoids; a review. Chem Biodivers 4:2495–2527PubMedGoogle Scholar
  140. Ramassamy C (2006) Emerging role of polyphenolic compounds in the treatment of neurodegenerative diseases: a review of their intracellular targets. Eur J Pharmacol 545:51–64PubMedGoogle Scholar
  141. Ramsden DB, Parsons RB, Ho SL, Waring RH (2001) The aetiology of idiopathic Parkinson’s disease. Mol Pathol 54(6):369–380PubMedCentralPubMedGoogle Scholar
  142. Reznichenko L, Amit T, Youdim MBH, Mandel S (2005) Green tea polyphenol (−)-epigallocatechin-3-gallate induces neurorescue of long-term serum-deprived PC12 cells and promotes neurite outgrowth. J Neurochem 93(5):1157–1167PubMedGoogle Scholar
  143. Reznichenko L, Kalfon L, Amit T, Youdim MBH, Mandel SA (2010) Low dosage of rasagiline and epigallocatechin gallate synergistically restored the nigrostriatal axis in MPTP-induced parkinsonism. Neurodegener Dis 7(4):219–231PubMedGoogle Scholar
  144. Rietveld A, Wiseman S (2003) Antioxidant effects of tea: evidence from human clinical trials. J Nutr 133:3285–3292Google Scholar
  145. Ritz B, Ascherio A, Checkoway H, Marder KS, Nelson LM, Rocca WA, Ross GW, Strickland D, Van Den Eeden SK, Gorell J (2007) Pooled analysis of tobacco use and risk of Parkinson disease. Arch Neurol 64(7):990–997PubMedGoogle Scholar
  146. Roowi S, Stalmach A, Mullen W, Lean ME, Edwards CA, Crozier A (2010) Green tea flavan-3-ols: colonic degradation and urinary excretion of catabolites by humans. J Agric Food Chem 58:1296–1304PubMedGoogle Scholar
  147. Saaksjarvi K, Knekt P, Rissanen H, Laaksonen MA, Reunanen A, Mannisto S (2008) Prospective study of coffee consumption and risk of Parkinson’s disease. Eur J Clin Nutr 62:908–915PubMedGoogle Scholar
  148. Saura-Calixto F, Serrano J, Goñi I (2007) Intake and bioaccessibility of total polyphenols in a whole diet. Food Chem 101:492–501Google Scholar
  149. Scalbert A, Williamson G (2000) Dietary intake and bioavailability of polyphenols. J Nutr 130(8S Suppl):85Google Scholar
  150. Scalbert A, Manach C, Morand C, Remesy C, Jimenez L (2005) Dietary polyphenols and the prevention of diseases. Crit Rev Food Sci Nutr 45(4):287–306PubMedGoogle Scholar
  151. Schaffer S, Halliwell B (2012) Do polyphenols enter the brain and does it matter? Some theoretical and practical considerations. Genes Nutr 7(2):99–109PubMedCentralPubMedGoogle Scholar
  152. Schrag A, Ben-Shlomo Y, Quinn N (2002) How valid is the clinical diagnosis of Parkinson’s disease in the community? J Neurol Neurosurg Psychiatry 73:529–534PubMedCentralPubMedGoogle Scholar
  153. Schroeter H, Bahia P, Spencer JPE, Sheppard O, Rattray M, Cadenas E, Rice-Evans C, Williams RJ (2007) (−)Epicatechin stimulates ERK-dependent cyclic AMP response element activity and up-regulates GluR2 in cortical neurons. J Neurochem 101(6):1596–1606PubMedGoogle Scholar
  154. Selkoe DJ (2008) Soluble oligomers of the amyloid beta-protein impair synaptic plasticity and behavior. Behav Brain Res 192(1):106–113PubMedCentralPubMedGoogle Scholar
  155. Sharma M, Dhamgaye S, Singh A, Prasad R (2012) Lipidome analysis reveals antifungal polyphenol curcumin affects membrane lipid homeostasis. Front Biosci 4:1195–1209Google Scholar
  156. Shults CW (2006) Lewy bodies. Proc Natl Acad Sci U S A 103:1661–1668PubMedCentralPubMedGoogle Scholar
  157. Sirk TW, Brown EF, Sum AK, Friedman M (2008) Molecular dynamics study on the biophysical interactions of seven green tea catechins with lipid bilayers of cell membranes. J Agric Food Chem 56:7750–7758PubMedGoogle Scholar
  158. Sirk TW, Friedman M, Brown EF (2011) Molecular binding of black tea theaflavins to biological membranes: relationship to bioactivities. J Agric Food Chem 59(8):3780–3787PubMedGoogle Scholar
  159. Skovronsky DM, Lee VM, Trojanowski JQ (2006) Neurodegenerative diseases: new concepts of pathogenesis and their therapeutic implications. Annu Rev Pathol Mech Dis 1:151–170Google Scholar
  160. Song WO, Chun OK (2008) Tea is the major source of flavan-3-ol and flavonol in the U.S. diet. J Nutr 138(8):1547Google Scholar
  161. Soto C (2003) Unfolding the role of protein misfolding in neurodegenerative diseases. Nat Rev Neurosci 4:49–60PubMedGoogle Scholar
  162. Soto-Otero R, Mendez-Alvarez E, Hermida-Ameijeiras A, Munoz Patino AM, Labaneira-Garcıa JL (2000) Autoxidation and neurotoxicity of 6-hydrodoe in the presence of some antioxidants: potential implication in relation to the pathogenesis of Parkinson’s disease. J Neurochem 74:1605–1612PubMedGoogle Scholar
  163. Spencer JPE (2008) Flavonoids: modulators of brain function? Br J Nutr 99:60–77Google Scholar
  164. Spencer JPE, Vauzour D, Rendeiro C (2009) Flavonoids and cognition: the molecular mechanisms underlying their behavioural effects. Arch Biochem Biophys 492(1–2):1–9PubMedGoogle Scholar
  165. Stalmach A, Troufflard S, Serafini M, Crozier A (2009) Absorption, metabolism and excretion of Choladi green tea flavan-3-ols by humans. Mol Nutr Food Res 53(Suppl 1):44–53Google Scholar
  166. Stevenson DE, Hurst RD (2007) Polyphenolic phytochemicals – just antioxidants or much more? Cell Mol Life Sci 64:2900–2916PubMedGoogle Scholar
  167. Sumpio BE, Cordova AC, Berke-Schlessel DW, Qin F, Chen QH (2006) Green tea, the “Asian paradox,” and cardiovascular disease. J Am Coll Surg 202(5):813–825PubMedGoogle Scholar
  168. Tan EK, Tan C, Fook-Chong SMC, Lum SY, Chai A, Chung H, Shen H, Zhao Y, Teoh ML, Yih Y, Pavanni R, Chandran VR, Wong MC (2003) Dose-dependent protective effect of coffee, tea, and smoking in Parkinson’s disease: a study in ethnic Chinese. J Neurol Sci 216(1):163–167PubMedGoogle Scholar
  169. Tan LC, Koh W-P, Yuan J-M, Wang R, Au W-L, Tan JH, Tan E-K, Yu MC (2008) Differential effects of black versus green tea on risk of Parkinson’s disease in the Singapore Chinese Health Study. Am J Epidemiol 167(5):553–560PubMedCentralPubMedGoogle Scholar
  170. Tanner CM, Ottman R, Goldman SM, Ellenberg J, Chan P, Mayeux R, Langston JW (1999) Parkinson disease in twins: an etiologic study. JAMA 281:341–346PubMedGoogle Scholar
  171. Tanner CM, Goldman SM, Aston DA, Ottman R, Ellenberg J, Mayeux R, Langston JW (2002) Smoking and Parkinson’s disease in twins. Neurology 58(4):581–588PubMedGoogle Scholar
  172. Toda T (2007) Molecular genetics of Parkinson’s disease. Brain Nerve 59(8):815–823PubMedGoogle Scholar
  173. Tsao R (2010) Chemistry and biochemistry of dietary polyphenols. Nutrients 2(12):1231–1246PubMedCentralPubMedGoogle Scholar
  174. Vafeiadou K, Vauzour D, Spencer JPE (2007) Neuroinflammation and its modulation by flavonoids. Endocr Metab Immune Disord Drug Targets 7(3): 211–224PubMedGoogle Scholar
  175. Vassallo N (ed) (2008) Polyphenols and health: new and recent advantages. Nova, New YorkGoogle Scholar
  176. Vauzour D (2012) Dietary polyphenols as modulators of brain functions: biological actions and molecular mechanisms underpinning their beneficial effects. Oxid Med Cell Longev 2012:914273PubMedCentralPubMedGoogle Scholar
  177. Vauzour D, Vafeiadou K, Rice-Evans C, Williams RJ, Spencer JP (2007) Activation of pro-survival Akt and ERK1/2 signalling pathways underlie the anti-apoptotic effects of flavanones in cortical neurons. J Neurochem 103(4):1355–1367PubMedGoogle Scholar
  178. Vauzour D, Ravaioli G, Vafeiadou K, Rodriguez-Mateos A, Angeloni C, Spencer JPE (2008) Peroxynitrite induced formation of the neurotoxins 5-S-cysteinyl-dopamine and DHBT-1: implications for Parkinson’s disease and protection by polyphenols. Arch Biochem Biophys 476(2):145–151PubMedGoogle Scholar
  179. Verstraeten SV, Keen CL, Schmitz HH, Fraga CG, Oteiza PI (2003) Flavan-3-ols and procyanidins protect liposomes against lipid oxidation and disruption of the bilayer structure. Free Radic Biol Med 34(1):84–92PubMedGoogle Scholar
  180. Wang H, Helliwell K (2001) Determination of flavonols in green and black tea leaves and green tea infusions by high performance liquid chromatography. Food Res Int 34(2–3):223–227Google Scholar
  181. Wang SH, Liu FF, Dong XY, Sun Y (2010) Thermodynamic analysis of the molecular interactions between amyloid beta-peptide 42 and (−)-epigallocatechin-3-gallate. J Phys Chem B 114(35):11576–11583PubMedGoogle Scholar
  182. Weinreb O, Mandel S, Amit T, Youdim MB (2004) Neurological mechanisms of green tea polyphenols in Alzheimer’s and Parkinson’s diseases. J Nutr Biochem 15:506–516PubMedGoogle Scholar
  183. Weinreb O, Amit T, Youdim MB (2008) The application of proteomics for studying the neurorescue activity of the polyphenol (−)-epigallocatechin-3-gallate. Arch Biochem Biophys 476:152–160PubMedGoogle Scholar
  184. Weinreb O, Amit T, Mandel S, Kupershmidt L, Youdim MB (2010) Neuroprotective multifunctional iron chelators: from redox-sensitive process to novel therapeutic opportunities. Antioxid Redox Signal 13:919–949PubMedGoogle Scholar
  185. Wheeler DS, Wheeler WJ (2004) The medicinal chemistry of tea. Drug Dev Res 61:45–65Google Scholar
  186. Williams RJ, Spencer JPE, Rice-Evans C (2004) Flavonoids: antioxidants or signalling molecules? Free Radic Biol Med 36(7):838–849PubMedGoogle Scholar
  187. Williamson G, Manach C (2005) Bioavailability and bioefficacy of polyphenols in humans. II. Review of 93 intervention studies. Am J Clin Nutr 81(Suppl 1):243–255Google Scholar
  188. Winner B, Jappelli R, Maji SK, Desplats PA, Boyer L, Aigner S, Hetzer C, Loher T, Vilar M, Campioni S, Tzitzilonis C, Soragni A, Jessberger S, Mira H, Consiglio A, Pham E, Masliah E, Gage FH, Riek R (2011) In vivo demonstration that alpha-synuclein oligomers are toxic. Proc Natl Acad Sci U S A 108: 4194–4199PubMedCentralPubMedGoogle Scholar
  189. Wirdefeldt K, Gatz M, Schalling M, Pedersen NL (2004) No evidence for heritability of Parkinson disease in Swedish twins. Neurology 63(2):305–311PubMedGoogle Scholar
  190. Wirdefeldt K, Adami H-O, Cole P, Trichopoulos D, Mandel J (2011) Epidemiology and etiology of Parkinson’s disease: a review of the evidence. Eur J Epidemiol 26(Suppl 1):1–58Google Scholar
  191. Wu AH, Arakawa K, Stanczyk FZ, Van Den Berg D, Koh WP, Yu MC (2005) Tea and circulating estrogen levels in postmenopausal Chinese women in Singapore. Carcinogenesis 26(5):976–980PubMedGoogle Scholar
  192. Xi YD, Yu HL, Ding J, Ma WW, Yuan LH, Feng JF, Xiao YX, Xiao R (2012) Flavonoids protect cerebrovascular endothelial cells through Nrf2 and PI3K from β-amyloid peptide-induced oxidative damage. Curr Neurovasc Res 9(1):32–41PubMedGoogle Scholar
  193. Yang D, Liu J, Tian C, Zeng Y, Zheng YH, Fang Q, Li HH (2010) Epigallocatechin gallate inhibits angiotensin II-induced endothelial barrier dysfunction via inhibition of the p38 MAPK/ HSP27 pathway. Acta Pharmacol Sin 31:1401–1406PubMedCentralPubMedGoogle Scholar
  194. Zecca L, Youdim MB, Riederer P, Connor JR, Crichton RR (2004) Iron, brain ageing and neurodegenerative disorders. Nat Rev Neurosci 5(11):863–873PubMedGoogle Scholar
  195. Zhang ZX, Román GC (1993) Worldwide occurrence of Parkinson’s disease: an updated review. Neuroepidemiology 12(4):195–208PubMedGoogle Scholar
  196. Zhu M, Rajamani S, Kaylor J, Han S, Zhou F, Fink AL (2004) The flavonoid baicalein inhibits fibrillation of alpha-synuclein and disaggregates existing fibrils. J Biol Chem 279(26):26846–26857PubMedGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2015

Authors and Affiliations

  1. 1.Department of Physiology and BiochemistryUniversity of MaltaMsidaMalta

Personalised recommendations